The Type 2 Diabetes market growth is driven by factors like increase in the prevalence of Type 2 Diabetes, investments in research and development, entry of emerging therapies during the study period 2019-2032.
The Type 2 Diabetes market report also offers comprehensive insights into the Type 2 Diabetes market size, share, Type 2 Diabetes epidemiology, emerging therapies, market drivers and barriers, ongoing clinical trials, key collaboration in the space, market uptake by key therapies and companies actively pushing Type 2 Diabetes market size growth forward.
Some of the key highlights from the Type 2 Diabetes Market Insights Report:
Strategise your business goals by understanding market dynamics @ Type 2 Diabetes Market Landscape
Type 2 Diabetes Overview
Type 2 diabetes, the most common type of diabetes, it is a disease that occurs when the blood glucose, also called blood sugar, is too high. People who are middle-aged or older are most likely to get this kind of diabetes. It used to be called adult-onset diabetes. But type 2 diabetes also affects kids and teens, mainly because of childhood obesity.
Type 2 Diabetes Diagnosis
The diagnostic procedure to confirm type 2 diabetes fasting plasma glucose (FPG) test, A1C test, random plasma glucose (RPG), and oral glucose tolerance test are carried out. For A1C, the normal range should be below 5.7%, fasting plasma glucose should be 99 mg/dL or below, and oral glucose tolerance should be 139 mg/dL or below
Type 2 Diabetes Treatment
Focusing on the chronic and severe nature of TD1 and TD2, the treatment approach for them is quite comprehensive; regularization of glucose metabolism and control of risk factors (e.g., arterial hypertension) is the key treatment target for type 2 diabetes. Metformin, which is the most commonly prescribed initial treatment for the condition, lowers blood sugar levels for patients by improving how their body handles insulin. Many other therapies including Alpha-glucosidase inhibitors, Amylin analogs, or agonists and sodium-glucose cotransporter-2 inhibitors, etc. are prescribed to treat type 2 diabetes.
Recent Breakthroughs in the Type 2 Diabetes Market:
FDA Approves Cognitive-Behavioral App for Adults With Type 2 Diabetes: A smartphone-based app designed to deliver cognitive-behavioral therapy (CBT) to adults with type 2 diabetes received marketing approval as a class II medical device from the US Food and Drug Administration (FDA) on July 10, becoming the first digital behavioral therapeutic device for people with diabetes to receive this designation for US patients.
Do you know the treatment paradigms for different countries? Download our Type 2 Diabetes Market Sample Report
Type 2 Diabetes Epidemiology Segmentation
DelveInsight’s Type 2 Diabetes market report is prepared on the basis of epidemiology model. It offers comprehensive insights to the Type 2 Diabetes historical patient pools and forecasted Type 2 Diabetes patients. The report provides in-depth data of various subtypes and for the same epidemiology is segmented further. The Type 2 Diabetes Market report proffers epidemiological analysis for the study period 2019-32 in the 7MM segmented into:
Visit for more @ Type 2 Diabetes Epidemiological Insights
Type 2 Diabetes Treatment Market
The Type 2 Diabetes market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Type 2 Diabetes market trends by analyzing the impact of current Type 2 Diabetes therapies on the market, unmet needs, drivers and barriers, and demand for better technology.
This segment gives a thorough detail of Type 2 Diabetes market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Type 2 Diabetes market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the Type 2 Diabetes market in 7MM is expected to witness a major change in the study period 2019-2032.
Type 2 Diabetes Emerging Therapy Assessment
Danuglipron (PF-06882961) – Pfizer
Danuglipron (PF-06882961), an oral small-molecule, GLP-1R agonist being developed by Pfizer. The drug is currently in Phase II of development. In Phase I, danuglipron demonstrated robust reductions in fasting plasma glucose of -66.6, -80.6, and -89.7 mg/dL at doses of 15, 70, and 120 mg respectively, compared to a -24.8 mg/dL reduction for placebo. Danuglipron also reduced HbA1c by -0.9, -1.2, and -1.2% at doses of 15, 70 and 120 mg respectively, compared to a -0.4% reduction for placebo-treated subjects. The results with the highest dose tested in a phase 2 trial show promising HbA1c lowering and weight loss.
ORMD-0801- Oramed
Oramed’s oral insulin ORMD-0801 is a Phase III drug has the potential to create a new paradigm in the treatment of diabetes by oral delivery of insulin at an earlier stage of treatment, potentially slowing disease progression and delaying or even eliminating late-stage complications. The drug is being evaluated in two Phase III trials ORA-D-013-1 and ORA-D-013-2 with the company anticipating the approval in 2024.
Type 2 Diabetes Key Companies
For more information, visit Type 2 Diabetes Market Analysis, Patient Pool, and Emerging Therapies
Scope of the Type 2 Diabetes Market Report:
Key Questions Answered in the Type 2 Diabetes Market Report 2032:
Table of Contents:
1 Type 2 Diabetes Market Key Comprehensive Insights
2 Type 2 Diabetes Market Report Introduction
3 Competitive Intelligence Analysis for Type 2 Diabetes
4 Type 2 Diabetes Market Analysis Overview at a Glance
5 Executive Summary of Type 2 Diabetes
6 Type 2 Diabetes Epidemiology and Market Methodology
7 Type 2 Diabetes Epidemiology and Patient Population
8 Type 2 Diabetes Patient Journey
9 Type 2 Diabetes Treatment Algorithm, Type 2 Diabetes Current Treatment, and Medical Practices
10 Key Endpoints in Type 2 Diabetes Clinical Trials
11 Type 2 Diabetes Marketed Therapies
12 Type 2 Diabetes Emerging Therapies
13 Type 2 Diabetes: 7 Major Market Analysis
14 Attribute analysis
15 Access and Reimbursement Overview of Type 2 Diabetes
16 Type 2 Diabetes Market Key Opinion Leaders Reviews
18 Type 2 Diabetes Market Drivers
19 Type 2 Diabetes Market Barriers
20 SWOT Analysis
21 Disclaimer
22 DelveInsight Capabilities
23 About DelveInsight
Related Reports:
Type 2 Diabetes Epidemiology 2032
DelveInsight’s “Type 2 Diabetes – Epidemiology Forecast to 2032” report delivers an in-depth understanding of the disease, historical and forecasted Type 2 Diabetes epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Type 2 Diabetes Pipeline 2023
“Type 2 Diabetes Pipeline Insights, 2023” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Type 2 Diabetes market. A detailed picture of the Type 2 Diabetes pipeline landscape is provided, which includes the disease overview and Type 2 Diabetes treatment guidelines.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Kritika RehaniEmail: Send EmailPhone: +91-9650213330Address:304 S. Jones Blvd #2432 City: Las VegasState: NevadaCountry: United StatesWebsite: https://www.delveinsight.com/
